Board of Directors
The Berlin Institute of Health at Charité (BIH) is led by a Board of Directors, responsible for strategic planning and implementation of the research program.
Professor Christopher Baum is the Chairman of the Board of Directors of the BIH. More information about Professor Baum can be found in his curriculum vitae.
Extended Board of Directors
In order to include the full-time scientific staff of the translational research area in the opinion-forming and decision-making of the directorate, an extended board of directors is formed. The extended board of directors advises the voting members of the board of directors with regard to its tasks. For this purpose, it may submit statements to the voting members and request information as well as the treatment of its motions.
The Extended Board of Directors consists of:
- Professor Axel R. Pries (Dean)
- four elected persons belonging to the full-time scientific staff of the Translational Research Unit.
The members will be announced shortly.
All activities of BIH are supervised by the Supervisory Board, which is also responsible for approving essential decisions such as the business plan, strategic planning, appointments, and investments.
|Deputies of the German Government|
|State Secretary Christian Luft||Federal Ministry of Education and Research, Chair|
|Deputies of the federal state of Berlin|
|State Secretary Steffen Krach||Office of The Senate for Science, Deputy Chair|
|Prof. Monika Jungbauer Gans||Scientific management, German Centre for Higher Education Research and Science Studies (DZHW)|
|Prof. Blanche Schwappach-Pignataro||Dean, Medical Center Hamburg-Eppendorf (UKE)|
|Dr. Christian Rommel||Head of Research and Development, Division Pharmaceuticals, BAYER AG|
|Annette Schavan||Federal Minister a. D.|
Scientific Advisory Board
The Scientific Advisory Board is responsible for providing the Executive Board and Supervisory Board with external specialized knowledge regarding future important research topics and ongoing scientific and strategic issues; it meets every six months. At present the Scientific Advisory Board consists of thirteen international experts in translational research and systems medicine.
Chair of the Scientific Advisory Board
Prof. Lina Badimon
Institute for Cardiovascular Science, Barcelona, Spain
Dr. André Terzic
Mayo Clinic, USA
|Lina Badimon||IR-Hospital Sta. Creu i S. Pau, Spain|
|Prof. Roland Lauster||TU Berlin, Germany|
|Prof. Teri Manolio||National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA|
|Prof. Miriam Merad||Mount Sinai School of Medicine, New York|
|Prof. David Moher||Ottawa Hospital Research Institute, Canada|
|Prof. Maritta Perälä-Heape||University of Oulu, Finland|
|Prof. Aviv Regev||Head of Genentech and Early Development, Roche, USA|
|Prof. Claudia Schmidtke||Herzzentrum Bad Segeberg, Patientenbeauftragte der Bundesregierung, Germany|
|Prof. Alan R. Shuldiner||University of Maryland School of Medicine, Baltimore, USA|
|André Terzic||Mayo Clinic, USA|
|Prof. Fabian Theis||Helmholtz Zentrum München, Germany|
|Prof. David A. Williams||Chief, Division of Hematology/Oncology, Boston Children’s Hospital / Harvard Medical School, USA|
|N. N.||N. N.|
|N. N.||N. N.|